Voya Investment Management LLC Sells 5,852 Shares of Becton Dickinson and Co (BDX)

Voya Investment Management LLC cut its holdings in shares of Becton Dickinson and Co (NYSE:BDX) by 5.9% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 93,097 shares of the medical instruments supplier’s stock after selling 5,852 shares during the period. Voya Investment Management LLC’s holdings in Becton Dickinson and were worth $22,302,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of the company. Ascension Asset Management LLC increased its position in shares of Becton Dickinson and by 4.2% during the second quarter. Ascension Asset Management LLC now owns 4,970 shares of the medical instruments supplier’s stock worth $1,191,000 after acquiring an additional 200 shares in the last quarter. Bfsg LLC increased its position in shares of Becton Dickinson and by 1.9% during the second quarter. Bfsg LLC now owns 10,515 shares of the medical instruments supplier’s stock worth $2,519,000 after acquiring an additional 201 shares in the last quarter. Toth Financial Advisory Corp increased its position in shares of Becton Dickinson and by 0.8% during the second quarter. Toth Financial Advisory Corp now owns 24,989 shares of the medical instruments supplier’s stock worth $5,986,000 after acquiring an additional 203 shares in the last quarter. Northwestern Mutual Wealth Management Co. increased its position in shares of Becton Dickinson and by 0.4% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 50,849 shares of the medical instruments supplier’s stock worth $12,181,000 after acquiring an additional 204 shares in the last quarter. Finally, Chesapeake Wealth Management increased its position in shares of Becton Dickinson and by 5.5% during the second quarter. Chesapeake Wealth Management now owns 4,179 shares of the medical instruments supplier’s stock worth $1,001,000 after acquiring an additional 219 shares in the last quarter. 86.96% of the stock is owned by institutional investors.

Shares of BDX stock opened at $259.98 on Monday. Becton Dickinson and Co has a 52-week low of $191.53 and a 52-week high of $263.37. The company has a quick ratio of 0.81, a current ratio of 1.23 and a debt-to-equity ratio of 0.95. The stock has a market capitalization of $69.13 billion, a price-to-earnings ratio of 27.42, a PEG ratio of 1.76 and a beta of 1.10.

Becton Dickinson and (NYSE:BDX) last issued its quarterly earnings data on Thursday, August 2nd. The medical instruments supplier reported $2.91 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.86 by $0.05. Becton Dickinson and had a net margin of 4.73% and a return on equity of 14.16%. The business had revenue of $4.28 billion during the quarter, compared to the consensus estimate of $4.25 billion. During the same period in the prior year, the firm posted $2.46 EPS. The firm’s quarterly revenue was up 41.0% compared to the same quarter last year. equities analysts expect that Becton Dickinson and Co will post 11.01 EPS for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 28th. Shareholders of record on Friday, September 7th will be given a $0.75 dividend. This represents a $3.00 dividend on an annualized basis and a yield of 1.15%. The ex-dividend date is Thursday, September 6th. Becton Dickinson and’s payout ratio is 31.65%.

BDX has been the subject of several recent research reports. KeyCorp reissued a “buy” rating and set a $264.00 target price on shares of Becton Dickinson and in a research report on Friday, August 3rd. Royal Bank of Canada reissued a “hold” rating and set a $248.00 target price on shares of Becton Dickinson and in a research report on Friday, August 3rd. ValuEngine downgraded shares of Becton Dickinson and from a “buy” rating to a “hold” rating in a research report on Tuesday, May 29th. Wells Fargo & Co boosted their target price on shares of Becton Dickinson and from $275.00 to $290.00 and gave the stock an “outperform” rating in a research report on Thursday, September 6th. They noted that the move was a valuation call. Finally, Citigroup boosted their target price on shares of Becton Dickinson and from $274.00 to $283.00 and gave the stock a “buy” rating in a research report on Wednesday, August 8th. Four research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $251.64.

About Becton Dickinson and

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. It operates in two segments, BD Medical and BD Life Sciences. The BD Medical segment offers syringes, pen needles, and other products for diabetes; needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; regional anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; skin antiseptic products; surgical and laparoscopic instrumentations; intravenous medication safety and infusion therapy delivery, and automated medication dispensing and supply management systems; medication inventory optimization and tracking systems; and prefillable drug delivery systems.

Read More: Are analyst ratings accurate?

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply